Development of tailor made peptide vaccines for renal cell carcinoma
| Project/Area Number |
22390305
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MINAMI Takafumi 近畿大学, 医学部, 助教 (70340809)
DE VELASCO Marco 近畿大学, 医学部, 助教 (20449838)
HARADA Mamoru 島根大学, 医学部, 教授 (50260716)
YOSHIMURA Kazuhiro 近畿大学, 医学部, 准教授 (20283757)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2011: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2010: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Keywords | 腎細胞癌 / 癌ワクチン / ペプチドワクチン / 免疫療法 / 腎細胞がん / 癌ワクチン療法 / CA9 / VEGFR / EPOR / HIF-1 / PDL-1 / ペプチド / ワクチン療法 |
|---|
| Research Abstract |
e have been working on the development of new MHC-class-I restricted peptide vaccines for five independent therapeutic targets and have identified a significant candidate EPORxx. We are preparing the application of a patent for this particular peptide vaccine. We also carried out phase-I/II clinical study with VEGFR1 peptide vaccines for 18 patients with disseminated renal cell carcinoma, and showed the safty and efficacy of the vaccination treatment.
|
Report
(4 results)
Research Products
(25 results)
-
-
[Journal Article] STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma2013
Author(s)
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S
-
Journal Title
Japan Immunotherapy SNPs-Study Group for Kidney Cancer
Volume: Eur Urol
Pages: 745-52
Related Report
Peer Reviewed
-
-
-
[Journal Article] STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.2013
Author(s)
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer.
-
Journal Title
Eur Urol.
Volume: 63
Issue: 4
Pages: 745-752
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system2011
Author(s)
Zennami K, Yoshikawa K, Kondo E, Nakamura K, Upsilonamada Y, De Velasco MA, Tanaka M, Uemura H, Shimazui T, Akaza H, Saga S, Ueda R, Honda N
-
Journal Title
Oncol Rep.
Volume: 26
Pages: 327-333
Related Report
Peer Reviewed
-
-
[Journal Article] Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-12011
Author(s)
Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H
-
Journal Title
Jpn J Clin Oncol
Volume: 41(1)
Pages: 17-24
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination2010
Author(s)
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K
-
Journal Title
Cancer Biol Ther
Volume: 10(12)
Pages: 1266-79
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
